Fundz

INVO Bioscience

SARASOTA, Florida, United States · Biotechnology, Healthcare, Health Care

At INVO bioscience, we are democratizing fertility. Our mission is to help people realize the dream of parenthood by increasing worldwide access to an efficient, effective, and connected experience in reproductive treatment. We are the manufacturers of INVOcell. The first and only FDA cleared, CE marked medical device used in intravaginal culture (IVC). INVOcell holds the gametes within the woman’

Key facts

Headquarters
SARASOTA, Florida, United States
Employees
19
Industries
Biotechnology, Healthcare, Health Care
Status
Public (IVF)
Website
invofertility.com
LinkedIn
Company page

Recent activity at INVO Bioscience

  • : SEC 8-K (8.01):
  • : SEC 8-K (1.01): On July 24, 2026, INVO Fertility Inc. entered into a Material Agreement with Alumni Capital LP, establishing an Any Market Purchase Agreement. Under this agreement, the Company may sell up to $15 million worth of its common stock, with potential to increase this to $50 million by mutual consent. Sales will occur at the Company's discretion and are intended to fund the expansion into additional profitable fertility clinics and for general corporate purposes. The execution of this agreement is subject to certain conditions, including the SEC's approval of a registration statement and prospectus. This agreement allows the Company significant control over the timing and price of share sales, affecting its funding strategies.
  • : SEC 8-K (1.01): On June 23, 2026, INVO Centers, LLC, a wholly-owned subsidiary of INVO Fertility Inc., entered into a Material Definitive Agreement with HRCFG, LLC to acquire 100% of the membership interests in HRCFG INVO LLC for a total purchase price of $175,001. This agreement, known as the Membership Interest Transfer Agreement (MITA), includes provisions for a $1.00 cash payment at closing, with the remainder to be paid from HRCFG's future cash flow and in installments starting October 2026. The acquisition integrates the Alabama joint venture clinic into the Company's financial statements, enhancing its operational presence in Alabama. The Sellers will also provide transition support for a period of 16 months to ensure a smooth transfer of operations.
  • : SEC 8-K (7.01): On June 16, 2026, INVO Fertility, Inc. furnished a Regulation FD Disclosure related to its investor presentation for the upcoming Planet MicroCap Conference scheduled for June 17, 2026. The presentation provides insights into the Company's current and long-term operations, performance, and industry conditions. It was made available on the Investors section of their website and includes forward-looking statements that carry cautionary language. The event signifies the Company's engagement with investors and highlights its strategic focus in the fertility industry.
  • : SEC 8-K (4.02):
  • : INVO Bioscience to merge with NAYA Biosciences
  • : SEC 8-K (7.01): On April 29, 2026, the Company issued a press release announcing that it had received a Letter, in compliance with Nasdaq Listing Rule 5810(b). This disclosure is significant as it pertains to regulatory compliance requirements for listed companies. The press release is detailed in Exhibit 99.1 attached to the filing. This event indicates ongoing communication with the Nasdaq regarding the company's listing status, potentially affecting investor confidence and market perception.
  • : SEC 8-K (8.01):
  • : SEC 8-K (1.01):
  • : INVO Fertility acquires Family Beginnings clinic

INVO Bioscience funding history

DateRoundAmount
Dec 2025Post-IPO Equity$4.0M
Apr 2023Seed$3.0M
Mar 2023Seed$500K
Feb 2023Seed$300K
Jan 2023Seed$500K

Leadership

  • Rebecca Messina, Director
  • Jeffrey Segal, Director
  • Barbara Ryan, Director
  • Matthew Szot, Director
  • Steven Shum, Executive Officer, Director
  • Trent Davis, Director
  • Kevin Doody, Director
  • Kathleen Karloff, Director
  • Steven Shum, Executive Officer, Director
  • Trent Davis, Director
  • Kevin Doody, Director
  • Michael Campbell, Executive Officer, Director

Verified email and direct lines for INVO Bioscience’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

INVO Bioscience files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

INVO Bioscience in the news

Companies similar to INVO Bioscience

About INVO Bioscience: questions and answers

What does INVO Bioscience do?

At INVO bioscience, we are democratizing fertility. Our mission is to help people realize the dream of parenthood by increasing worldwide access to an efficient, effective, and connected experience in reproductive treatment. We are the manufacturers of INVOcell. The first and only FDA cleared, CE marked medical device used in intravaginal culture (IVC). INVOcell holds the gametes within the woman’

Where is INVO Bioscience headquartered?

INVO Bioscience is headquartered in SARASOTA, Florida, United States.

How many employees does INVO Bioscience have?

INVO Bioscience has about 19 employees.

Has INVO Bioscience raised funding?

Yes. Fundz has recorded 5 funding events for INVO Bioscience. The most recent, Post-IPO Equity of $4.0M, was in Dec 2025.

What is the latest news on INVO Bioscience?

On Aug 28, 2026, SEC 8-K (8.01):

Is INVO Bioscience a public company?

Yes. INVO Bioscience is publicly traded under the ticker IVF.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches INVO Bioscience across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.